Updated: January 22, 2026

Vemlidy Shortage Update: What Patients Need to Know in 2026

Author

Peter Daggett

Summarize with AI

Is Vemlidy in Shortage in 2026?
Why Patients Experience Access Difficulties
A Brief Timeline of Vemlidy Availability
Why You Should Never Stop Vemlidy Without Guidance
What to Do If You're Affected

Vemlidy is not in FDA shortage, but access barriers are real. Here's the 2026 status of Vemlidy availability, what's causing the problem, and what hepatitis B patients can do.

If your pharmacist has told you they need to order Vemlidy, or if you've been bounced between pharmacies trying to fill your prescription, you may be wondering: is Vemlidy in shortage? The answer is nuanced — and understanding the full picture is key to keeping your hepatitis B treatment on track.

Is Vemlidy in Shortage in 2026?

As of early 2026, Vemlidy (tenofovir alafenamide) is NOT listed on the FDA Drug Shortage Database. Gilead Sciences continues to manufacture and supply the drug. There is no production outage, raw material shortage, or distribution failure affecting the national supply.

However — and this is an important distinction — not being in official shortage does not mean patients can easily fill it at any pharmacy. The real barriers are structural: cost, specialty pharmacy routing, and the absence of a US generic.

Why Patients Experience Access Difficulties

The practical access barriers patients face in 2026 include:

No US-marketed generic. Vemlidy remains a brand-only medication at $1,500–$1,800/month retail. While the FDA has approved generic manufacturing, no standalone generic TAF has reached American pharmacies as of early 2026.

Retail pharmacy understocking. At $1,500+ per unit, most retail pharmacies don't keep Vemlidy on the shelf. They order it on demand — typically a 3–5 day wait.

Specialty pharmacy routing. Many insurance plans route Vemlidy through specialty pharmacy networks. If a patient doesn't know this and walks into a retail pharmacy, the prescription may be rejected or delayed.

Prior authorization requirements. Some insurers require prior authorization before covering Vemlidy, particularly if the patient hasn't tried TDF first. PA processing can take days or weeks.

A Brief Timeline of Vemlidy Availability

November 2016: FDA approves Vemlidy for adults with chronic hepatitis B and compensated liver disease.

2022: Approval expanded to pediatric patients 12 years and older.

2024: Approval further expanded to children 6 years and older weighing at least 25 kg (55 lbs).

2025: Generic emtricitabine/TAF combination authorized in the EU by Viatris, but no standalone US generic for Vemlidy enters the market.

Early 2026: FDA has approved generic TAF manufacturing, but no commercial US generic product yet available. Specialty access barriers persist.

Why You Should Never Stop Vemlidy Without Guidance

The FDA requires Vemlidy to carry a boxed warning — the agency's strongest safety notice — about severe acute exacerbations of hepatitis B following treatment discontinuation. When patients stop antiviral therapy, the hepatitis B virus can rebound rapidly, causing liver inflammation that in some cases leads to acute liver failure.

If you're facing a fill delay or access problem, call your doctor before you run out. They can help you bridge to another medication, contact the pharmacy on your behalf, or emergency-authorize a different pharmacy for your prescription.

What to Do If You're Affected

Don't panic — Vemlidy is available, just not at every pharmacy.

Call specialty pharmacies (CVS Specialty, Walgreens Specialty, Accredo) — they reliably stock Vemlidy.

Use medfinder to find which pharmacies in your area have it in stock without spending hours on hold.

Ask your insurance plan which specialty pharmacy network they use for Vemlidy.

If you're uninsured, apply for Gilead Advancing Access (gileadadvancingaccess.com or 1-800-226-2056) for free medication.

Contact your doctor's office if you might run out — they can help you avoid a dangerous medication gap.

If you're exploring your options, see our guide to alternatives to Vemlidy if you can't fill your prescription.

Frequently Asked Questions

No. As of early 2026, Vemlidy is not listed on the FDA Drug Shortage Database. Gilead Sciences continues to manufacture and supply it. However, many patients experience practical access difficulties due to specialty pharmacy routing, high cost, and lack of a US-marketed generic.

As of early 2026, the FDA has approved generic tenofovir alafenamide manufacturing, but no standalone commercial generic product is available at US pharmacies yet. A generic combination product (emtricitabine/TAF) was approved in the EU in 2025, which may signal eventual US availability, but no confirmed timeline has been announced.

Stopping Vemlidy abruptly can cause severe, sometimes life-threatening flare-ups of hepatitis B. This risk is listed as a boxed warning on the medication. If you cannot fill your prescription, contact your doctor before you run out. Never stop Vemlidy without medical supervision.

Vemlidy is a brand-name specialty medication with no US-marketed generic as of early 2026. Without generic competition, Gilead Sciences sets the price at approximately $1,500–$1,800 per month retail. However, Gilead's co-pay assistance program can reduce costs to $0 for eligible commercially insured patients, and the Advancing Access program provides free medication to qualifying uninsured patients.

Yes. medfinder calls pharmacies in your area to find which ones have Vemlidy in stock and can fill your prescription. You provide your medication, dosage, and zip code — and results are texted back to you. This saves significant time compared to calling pharmacies yourself.

Medfinder Editorial Standards

Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.

Read our editorial standards